Syndax Pharmaceuticals Inc. (NASDAQ: ) stock hit a 52-week low, falling to $12.75, as the company faces a challenging market environment. According to InvestingPro data, technical indicators suggest that the stock is in oversold territory, with a market capitalization of $1.1 billion. This latest price level shows a significant drop over the past year, with the stock experiencing a one-year change of -40.79%. Investors are closely watching the biopharmaceutical company, known for its work in cancer therapies, as it navigates a period of volatility and investor skepticism. While the company maintains a strong financial position with more cash than debt and a healthy current ratio of 7x, InvestingPro The analysis reveals additional insights through comprehensive research reports covering 1,400+ US stocks. The 52-week low serves as a critical point of interest for potential buyers looking for undervalued opportunities, while existing shareholders consider the company’s long-term prospects amid current trends in the health care sector. Analyst price targets range from $18 to $51, suggesting significant upside potential, although the company faces challenges with weak gross profit margins and expected negative earnings for the future. year.

In other recent news, Syndax Pharmaceuticals announced various developments. The company has eliminated the role of Chief Medical (TASE:) Officer, and Dr. Catherine Madigan, who held the position, has left. In addition, Syndax’s drug Revuforj received approval for the treatment of R/R KMT2Am acute leukemias. This approval led TD Cowen to reiterate a Buy rating on the company’s stock.

HC Wainwright also raised the price target on Syndax from $49.00 to $51.00, maintaining a Buy rating in light of Revuforj’s FDA approval. However, Scotiabank (TSX:) reduced its price target for Syndax to $18 due to potential risks of FDA approval for revumenib, while Goldman Sachs lowered its price target from $33 to $31, which maintains a Buy rating due to concerns about QTc prolongations and differentiation syndrome in the AUGMENT- 101 trial.

On the financial front, Syndax announced a $350 million royalty agreement with Royalty Pharma for Niktimvo during its Q3 2024 earnings call, reporting $399.6 million in cash as of September 30, with Q3 expenses of operations of $102.1 million. These are the latest developments in Syndax Pharmaceuticals’ journey as it continues to navigate clinical trials and financial milestones.

This article was created with the support of AI and reviewed by an editor. For more information see our T&C.